RecallDepth
Class II Terminated

Diltiazem Hydrochloride Extended-Release Capsules, USP, 360 mg; Rx only; 90-count bottles, Manufactured by: Sun Pharmaceutical Industries Ltd. Halol-Baroda Highway, Halol-389350, Gujarat, India; Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512, NDC 47335-679-81

This recall has been terminated (originally issued February 8, 2023).

Company
Sun Pharmaceutical Industries Inc
Recall Initiated
January 13, 2023
Posted
February 8, 2023
Recall Number
D-0262-2023
Voluntary / Mandated
Voluntary: Firm initiated
Quantity
Lot # HAC3120A: 6912 Bottles; Lot # HAC3121A: 6792 Bottles; Lot # HAC4460A: 6816 Bottles; Lot # HAD0365A: 6744 Bottles; Lot # HAD1452A: 6840 Bottles
Firm Location
Princeton, NJ, United States
Official Source
View on FDA website ↗

Reason for Recall

Failed Impurity (Deacetyl Diltiazem Hydrochloride) specification during stability testing and failed dissolution testing at FDA laboratory.

Distribution

Nationwide in the U.S.

Lot / Code Info

Lot #: HAC3120A, HAC3121A, Exp. 04/2023; HAC4460A, Exp. 10/2023; HAD0365A, Exp. 12/2023; HAD1452A, Exp. 02/2024.

More recalls by Sun Pharmaceutical Industries Inc

View all recalls by this company →

Other recent Class II Drug recalls